Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06931990 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Explore the Safety, Tolerability, Efficacy, and Pharmacokinetics of LT-002-158 Tablets in Chinese Adult Subjects With Atopic Dermatitis

StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 2 years 3 months later Oct 30, 2025 → Feb 17, 2028
See other at-risk trials from Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.

Record History

  1. Primary completion pushed from Oct 30, 2025 to Feb 17, 2028 Recruitment opened · Completion pushed from Dec 30, 2025 to Mar 30, 2028 · Study sites: 0 to 1 · 1 morev2 Show 4 more changesShow less
    • Recruitment opened
    • Completion pushed from Dec 30, 2025 to Mar 30, 2028
    • Study sites: 0 to 1
    • Start date changed from estimate of Apr 15, 2025 to Jun 4, 2025
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is an Ic/II phase clinical trial conducted in Chinese subjects with moderate to severe atopic dermatitis. The phase Ic study is a randomized, open label, parallel group design, mainly evaluating the safety and tolerability of LT-002-158 tablets in subjects with moderate to severe atopic dermatitis. The phase II study is a randomized, double-blind, placebo-controlled, parallel group design, with a single arm design for extended treatment, mainly exploring the efficacy of LT-002-158 tablets in the treatment of moderate to severe atopic dermatitis subjects.
Trial Details
NCT Number NCT06931990
Lead Sponsor Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.
Conditions Atopic Dermatitis (AD)
Enrollment 24 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov